Oversight and monitoring
The MANCAN2 TMG is responsible for trial progress oversight and is chaired by the chief investigator. The TMG includes representatives with expertise in oncology, nursing, psychology, process evaluation and medical statistics with a patient and public involvement member and SCTU staff involved in the day-to-day management of the trial.No DMEC will be convened for MANCAN2; this role will be assumed by the trial steering committee. An independent (TSC) for MANCAN2 exists to safeguard the interests of trial participants and to monitor the main outcome measures and overall conduct of the trial on behalf of the sponsor and funder. Monitoring is conducted centrally by the SCTU trial management team.